← Back to Search

Statins

Rosuvastatin for Coronary Artery Disease (PREDICT Trial)

Phase 4
Waitlist Available
Research Sponsored by General University Hospital, Prague
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
stable angina pectoris
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up the patients will be followed in the study for one year.
Awards & highlights

PREDICT Trial Summary

The prediction of extent and risk profile of coronary atherosclerosis based on clinical evaluation and non-invasive techniques. Detailed analysis of plaque volume, plaque composition, risk plaque features and shear stress (WSS) changes during lipid lowering therapy (rosuvastatin 40mg) from 3D vessel reconstruction. Prediction of changes in coronary arteries based on changes in non-invasive examinations. Examination of WSS influence on atherosclerosis development and changes of WSS during lipid lowering therapy.

Eligible Conditions
  • Coronary Artery Disease

PREDICT Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

PREDICT Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~the patients will be followed in the study for one year
This trial's timeline: 3 weeks for screening, Varies for treatment, and the patients will be followed in the study for one year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
The prediction of plaque volume and plaque composition.
Secondary outcome measures
Prediction of changes in plaque volume and plaque composition

Side effects data

From 2018 Phase 4 trial • 12 Patients • NCT03074630
8%
genital fungal infection
100%
80%
60%
40%
20%
0%
Study treatment Arm
Adverse Events

PREDICT Trial Design

1Treatment groups
Experimental Treatment
Group I: RosuvastatinExperimental Treatment1 Intervention
All patients will be using rosuvastatin 40 mg
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Rosuvastatin
FDA approved

Find a Location

Who is running the clinical trial?

Ministry of Health, Czech RepublicOTHER_GOV
24 Previous Clinical Trials
39,579 Total Patients Enrolled
3 Trials studying Coronary Artery Disease
1,240 Patients Enrolled for Coronary Artery Disease
Czech Ministry of EducationOTHER_GOV
1 Previous Clinical Trials
200 Total Patients Enrolled
1 Trials studying Coronary Artery Disease
200 Patients Enrolled for Coronary Artery Disease
Loyola University ChicagoOTHER
20 Previous Clinical Trials
12,528 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
The Prediction of Extent and Risk Profile of Coronary Atherosclerosis and Their Changes During Lipid-lowering Therapy Based on Non-invasive Techniques
Tomas Kovarnik 2012. "The Prediction of Extent and Risk Profile of Coronary Atherosclerosis and Their Changes During Lipid-lowering Therapy Based on Non-invasive Techniques". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01773512.
All > Atherosclerosis
~5 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top